Acute Myelomonocytic Leukemia Overview

Save information for later
Sign Up

Learn About Acute Myelomonocytic Leukemia

View Main Condition: Leukemia

What is the definition of Acute Myelomonocytic Leukemia?
A rare acute myeloid leukemia disorder characterized by increased blast cells (myeloblasts, monoblast, and/or promonoblasts), representing more than 20% of the total bone marrow (BM) or peripheral blood differential counts, with 20-80% of BM cells being of monocytic lineage. Clinical presentation is the result of bone marrow involvement and extramedullary infiltration by the leukemic cells and includes asthenia, pallor, fever, dizziness, respiratory symptoms, easy bruising, bleeding disorders, and neurological deficits. Gingival hyperplasia, organomegaly, especially hepatosplenomegaly, and lymphadenopathy may also be associated.
What are the alternative names for Acute Myelomonocytic Leukemia?
  • Acute myelomonocytic leukemia
  • Acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)
  • AML M4
  • AML-M4
  • AMMoL
  • Acute myeloblastic leukemia type 4
  • AML with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)
  • AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22)
  • Acute myelomonocytic leukemia
  • CBFB-MYH11
Who are the top Acute Myelomonocytic Leukemia Local Doctors?
Dr. Mark T. Schroeder
Oncology | Hematology
Dr. Mark T. Schroeder
Oncology | Hematology
353 Fairmont Blvd., 
Rapid City, SD 
 (1.7 mi)
605-719-2300
Languages Spoken:
English

Mark Schroeder is an Oncologist and a Hematologist in Rapid City, South Dakota. Dr. Schroeder and is rated as an Experienced provider by MediFind in the treatment of Acute Myelomonocytic Leukemia. His top areas of expertise are B-Cell Lymphoma, Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia (CLL), and Pancreatic Ductal Adenocarcinoma.

Dr. Josh B. Henderson
Internal Medicine
Dr. Josh B. Henderson
Internal Medicine

Mobridge Regional Hospital

1309 10th Ave W, 
Mobridge, SD 
 (169.8 mi)
605-845-3692
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Josh Henderson is an Internal Medicine provider in Mobridge, South Dakota. Dr. Henderson and is rated as a Distinguished provider by MediFind in the treatment of Acute Myelomonocytic Leukemia. His top areas of expertise are Acute Myelomonocytic Leukemia, Postmenopausal Osteoporosis, Osteoporosis, and Maturity Onset Diabetes of the Young. Dr. Henderson is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Dr. Richard J. Conklin
Hematology Oncology | Hematology | Oncology
Dr. Richard J. Conklin
Hematology Oncology | Hematology | Oncology

Avera Mckennan

310 S Penn St, 
Aberdeen, SD 
 (251.9 mi)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Richard Conklin is a Hematologist Oncology specialist and a Hematologist in Aberdeen, South Dakota. Dr. Conklin and is rated as a Distinguished provider by MediFind in the treatment of Acute Myelomonocytic Leukemia. His top areas of expertise are Acute Myelomonocytic Leukemia, Familial Colorectal Cancer, Paget Disease of the Breast, Familial Pancreatic Cancer, and Bone Marrow Aspiration. Dr. Conklin is currently accepting new patients.

View All Doctors
What are the latest Acute Myelomonocytic Leukemia Clinical Trials?
Phase II Study of the Targeted Mutant IDH2 Inhibitor Enasidenib in Combination With Azacitidine for Relapsed/Refractory AML
Phase II Study of the Targeted Mutant IDH2 Inhibitor Enasidenib in Combination With Azacitidine for Relapsed/Refractory AML
Who is this study for: Adult patients with Acute Myeloid Leukemia or Bilineage Leukemia
Enrollment Status: Recruiting
Publish Date: February 26, 2025
Intervention Type: Drug
Study Drugs: Azacitidine, Enasidenib
Study Phase: Phase 2

Summary: This phase II trial studies how well enasidenib and azacitidine work in treating patients with IDH2 gene mutation and acute myeloid leukemia that has come back (recurrent) or does not respond to treatment (refractory). Enasidenib and azacitidine may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Match to trials
Find the right clinical trials for you in under a minute
Get started
Phase 1/2 Clinical Trial of S227928, an Anti-CD74 Antibody-Drug Conjugate Targeting MCL-1, as a Single Agent and in Combination With Venetoclax in Patients With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)/AML, or Chronic Myelomonocytic Leukemia (CMML)
Phase 1/2 Clinical Trial of S227928, an Anti-CD74 Antibody-Drug Conjugate Targeting MCL-1, as a Single Agent and in Combination With Venetoclax in Patients With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)/AML, or Chronic Myelomonocytic Leukemia (CMML)
Enrollment Status: Recruiting
Publish Date: February 25, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2

Summary: The objective of this study is to determine the safety, tolerability, and anti-leukemic activity of S227928 as single agent and in combination with venetoclax, and to determine the recommended Phase 2 dose (RP2D) of this combination. The study will begin as a Phase 1 Dose Escalation study to determine the RP2D and then will transition to a Phase 2 Dose Expansion study to assess the efficacy of the...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center